The European Court of Justice, the European Union’s highest court, backed a fine issued to AstraZeneca after the pharmaceutical company was found to have hampered competition by blocking rivals from its ulcer drug Losec and selling it for less money. The fine is a validation of the General Court’s, Europe’s second-highest court, 2010 decision to support the European Commission’s finding that AstraZeneca had breached competition law, but is also supportive of of the General Court’s decision to lower the fine originally administered by the Commission of €60 million to €52.5 million.
Featured News
French Antitrust Raid Targets Passenger Transport Sector
Feb 18, 2026 by
CPI
FTC Moves to Bring Back Rules To Make It Easier for Consumers to Cancel Subscriptions
Feb 18, 2026 by
CPI
California Lawmaker Backs Sweeping Antitrust Overhaul
Feb 18, 2026 by
CPI
Brazil’s Competition Authority Probes Microsoft’s Jumpstart Program Over Browser Concerns
Feb 18, 2026 by
CPI
The Battle Between CFTC and State Regulators Over Prediction Markets Spreads to Capitol Hill
Feb 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Hub-&-Spoke Conspiracies
Jan 26, 2026 by
CPI
A Data Analytics Company as the Hub in a Hub-and-Spoke Cartel
Jan 26, 2026 by
Joseph Harrington
Hub and Spoke Cartels
Jan 26, 2026 by
Patrick Van Cayseele
Hub-and-Spoke Collusion or Vertical Exclusion? Identifying the Rim in Hub-and-Spoke Conspiracies
Jan 26, 2026 by
Rosa Abrantes-Metz, Pedro Gonzaga, Laura Ildefonso & Albert Metz
The Algorithmic Middleman in a Hub-and-Spoke Conspiracy: Divergent Court Decisions and the Expanding Patchwork of State and Local Regulations
Jan 26, 2026 by
Bradley C. Weber